DE602004024963D1 - Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer - Google Patents
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauerInfo
- Publication number
- DE602004024963D1 DE602004024963D1 DE602004024963T DE602004024963T DE602004024963D1 DE 602004024963 D1 DE602004024963 D1 DE 602004024963D1 DE 602004024963 T DE602004024963 T DE 602004024963T DE 602004024963 T DE602004024963 T DE 602004024963T DE 602004024963 D1 DE602004024963 D1 DE 602004024963D1
- Authority
- DE
- Germany
- Prior art keywords
- prodrug
- tablets
- drug
- active pharmaceutical
- beads containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 5
- 239000000651 prodrug Substances 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 239000011324 bead Substances 0.000 abstract 3
- 239000002775 capsule Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001055 chewing effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45425303P | 2003-03-13 | 2003-03-13 | |
PCT/US2004/007910 WO2004082620A2 (en) | 2003-03-13 | 2004-03-15 | Oxycodone conjugates with lower the abuse potential and extended duration of action |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004024963D1 true DE602004024963D1 (de) | 2010-02-25 |
Family
ID=33029866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004024963T Expired - Lifetime DE602004024963D1 (de) | 2003-03-13 | 2004-03-15 | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer |
Country Status (8)
Country | Link |
---|---|
US (2) | US7230005B2 (de) |
EP (1) | EP1603597B1 (de) |
JP (1) | JP2006520392A (de) |
AT (1) | ATE454169T1 (de) |
CA (1) | CA2518834A1 (de) |
DE (1) | DE602004024963D1 (de) |
MX (1) | MXPA05009757A (de) |
WO (1) | WO2004082620A2 (de) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
ES2374717T3 (es) | 1999-10-29 | 2012-02-21 | Euro-Celtique S.A. | Formulaciones de hidrocodona de liberación controlada. |
WO2005032474A2 (en) * | 2003-09-30 | 2005-04-14 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
PT2939696E (pt) | 2001-10-18 | 2016-06-17 | Nektar Therapeutics | Conjugados poliméricos de antagonistas de opióides |
US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
AU2003219863C1 (en) * | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
PT1644019E (pt) | 2003-05-29 | 2012-05-23 | Shire Llc | Compostos de anfetamina resistentes ao abuso |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
SI1694363T1 (sl) | 2003-12-16 | 2014-03-31 | Nektar Therapeutics | Monodisperzni PEG-ilirani naloksolni sestavki |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
TWI483944B (zh) | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | 含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝 |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8394812B2 (en) | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
EP2402005B1 (de) | 2005-08-24 | 2020-12-16 | Endo Pharmaceuticals Inc. | Nalbuphin-Formulierungen mit verzögerter Freisetzung |
BRPI0712819B8 (pt) | 2006-05-26 | 2021-05-25 | Pharmacofore Inc | composto para liberação controlada de opióides fenólicos, processo para a preparação do referido composto e composição farmacêutica |
CN101528264B (zh) * | 2006-05-26 | 2014-02-26 | 特色疗法股份有限公司 | 酚类阿片样物质的受控释放 |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
EP2064215B1 (de) * | 2006-09-22 | 2015-07-15 | Zynerba Pharmaceuticals, Inc. | Transdermal freisetzbare buprenorphin-prodrugs und missbrauchsichere zusammensetzungen daraus |
RU2009125597A (ru) * | 2006-12-05 | 2011-01-20 | Ньюроджесэкс, Инк. (Us) | Пролекарства и способы их получения и применения |
WO2008101187A2 (en) * | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | Pro-drugs of peripheral phenolic opioid antagonists |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
ES2534741T3 (es) * | 2007-03-12 | 2015-04-28 | Nektar Therapeutics | Conjugados de oligómero-agonista opioide |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
JP2010535238A (ja) | 2007-07-30 | 2010-11-18 | オールトランツ インコーポレイティド | カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法 |
US9023860B2 (en) | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
WO2009092073A2 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
EP2254561A2 (de) * | 2008-03-26 | 2010-12-01 | AllTranz Inc. | Missbrauchssichere transdermale formulierungen von opiat-agonisten und -agonist-antagonisten |
KR101690094B1 (ko) | 2008-05-09 | 2016-12-27 | 그뤼넨탈 게엠베하 | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 |
JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス, インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
WO2009143297A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Carbonate prodrugs and methods of using the same |
CN102159249A (zh) * | 2008-09-16 | 2011-08-17 | 尼克塔治疗公司 | 具有低滥用潜在性的聚乙二醇化阿片样物质 |
EP2398805A1 (de) * | 2009-02-23 | 2011-12-28 | Mallinckrodt LLC | Quaternäre (+)-morphinaniumsalze und verfahren zu ihrer herstellung |
EP2398806A1 (de) * | 2009-02-23 | 2011-12-28 | Mallinckrodt LLC | (+)-morphinanium-n-oxide und verfahren zu ihrer herstellung |
US8563724B2 (en) * | 2009-02-23 | 2013-10-22 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
AU2010231126A1 (en) * | 2009-04-02 | 2011-10-13 | Shire Llc | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof |
US10849981B2 (en) | 2009-07-02 | 2020-12-01 | KemPham, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
US8871780B2 (en) | 2009-07-02 | 2014-10-28 | Kempharm, Inc. | Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof |
WO2011009020A2 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
CN105503889B (zh) * | 2009-07-21 | 2019-12-24 | 尼克塔治疗公司 | 低聚物-阿片样激动剂轭合物 |
NZ596667A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Hot-melt extruded controlled release dosage form |
BR112012001466A2 (pt) * | 2009-07-22 | 2020-08-11 | Grünenthal GmbH | forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem |
US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
US20110262359A1 (en) * | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
EP2568977A1 (de) | 2010-05-11 | 2013-03-20 | Cima Labs Inc. | Alkoholresistente metoprololhaltige orale retard-dosierformen |
PE20131126A1 (es) | 2010-09-02 | 2013-10-21 | Gruenenthal Chemie | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
CA2814763C (en) * | 2011-01-11 | 2019-05-28 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
JP6148182B2 (ja) | 2011-03-09 | 2017-06-14 | シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. | 複素環式リンカーを有する活性薬剤プロドラッグ |
CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
CN103917543A (zh) | 2011-09-08 | 2014-07-09 | 马林克罗特有限公司 | 在不分离中间体的情况下制备生物碱 |
RU2573388C2 (ru) | 2011-10-26 | 2016-01-20 | Кемфарм Инк. | Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение |
EP2819656A1 (de) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Fälschungssichere dosierform mit einer pharmazeutisch aktiven verbindung und einem anionischen polymer |
SI2838512T1 (sl) | 2012-04-18 | 2018-11-30 | Gruenenthal Gmbh | Pred posegi in prehitrim sproščanjem odporna farmacevtska oblika odmerka |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
JP6382187B2 (ja) * | 2012-06-21 | 2018-08-29 | フォスフォレックス,インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
CA2913558C (en) * | 2013-05-24 | 2021-06-29 | Rhodes Technologies | Opioid ketal compounds and uses thereof |
CA2913209A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
KR20160031526A (ko) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형 |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
BR112016010482B1 (pt) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | Preparação de uma composição farmacêutica em pó por meio de criomoagem |
CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
EP3148512A1 (de) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel |
SG11201704178UA (en) * | 2014-11-25 | 2017-06-29 | Kempharm Inc | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone |
CA2969221C (en) | 2014-12-02 | 2021-01-12 | Travis Mickle | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof |
EP3234604A4 (de) * | 2014-12-17 | 2017-11-29 | Siemens Healthcare Diagnostics Inc. | Konjugate für tests für oxycodon und oxymorphon |
CA2983642A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10017519B2 (en) * | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
US10226456B2 (en) | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
US9987269B2 (en) * | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
GB2556817B (en) | 2015-10-01 | 2019-11-06 | Elysium Therapeutics Inc | Polysubunit opioid prodrugs resistant to overdose and abuse |
WO2018170465A1 (en) | 2017-03-17 | 2018-09-20 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
AU2019224127B2 (en) * | 2018-02-23 | 2021-12-09 | Rhodes Technologies | Novel opioid compounds and uses thereof |
US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
EP3965733A4 (de) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | Esketamin enthaltende missbrauchssichere darreichungsformen |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE638369A (de) * | 1962-10-10 | |||
GB1300419A (en) * | 1969-05-16 | 1972-12-20 | Organon Labor Ltd | New morphinone derivatives and their preparation |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
WO1983000150A1 (en) * | 1981-07-02 | 1983-01-20 | Walton, Alan, G. | Glycosaminoglycan drug complexes |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4785000A (en) * | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5194581A (en) * | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
US5130126A (en) * | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5176907A (en) * | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
JP2001526229A (ja) * | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク,エス.エイ. | オピオイド投薬剤形の乱用を防止する方法 |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
ES2412409T3 (es) * | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
US20030064122A1 (en) | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
AU2002305816B2 (en) * | 2001-06-05 | 2008-04-10 | Psivida Us Inc. | Sustained-release analgesic compounds |
AU2003219863C1 (en) * | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
US20040058946A1 (en) * | 2002-07-05 | 2004-03-25 | Buchwald Stephen L. | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals |
-
2004
- 2004-03-15 DE DE602004024963T patent/DE602004024963D1/de not_active Expired - Lifetime
- 2004-03-15 WO PCT/US2004/007910 patent/WO2004082620A2/en active Search and Examination
- 2004-03-15 AT AT04757462T patent/ATE454169T1/de not_active IP Right Cessation
- 2004-03-15 US US10/800,898 patent/US7230005B2/en active Active
- 2004-03-15 CA CA002518834A patent/CA2518834A1/en not_active Abandoned
- 2004-03-15 MX MXPA05009757A patent/MXPA05009757A/es active IP Right Grant
- 2004-03-15 EP EP04757462A patent/EP1603597B1/de not_active Expired - Lifetime
- 2004-03-15 JP JP2006507215A patent/JP2006520392A/ja active Pending
-
2007
- 2007-04-30 US US11/742,566 patent/US20070203165A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006520392A (ja) | 2006-09-07 |
EP1603597A2 (de) | 2005-12-14 |
CA2518834A1 (en) | 2004-09-30 |
WO2004082620A3 (en) | 2005-09-15 |
US7230005B2 (en) | 2007-06-12 |
US20040204434A1 (en) | 2004-10-14 |
MXPA05009757A (es) | 2005-12-05 |
ATE454169T1 (de) | 2010-01-15 |
US20070203165A1 (en) | 2007-08-30 |
WO2004082620A2 (en) | 2004-09-30 |
EP1603597B1 (de) | 2010-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004024963D1 (de) | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer | |
EP1782834A3 (de) | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer | |
WO2011163594A3 (en) | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives | |
WO2008069941A3 (en) | Modified release ibuprofen solid oral dosage form | |
EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
NZ597108A (en) | Prodrugs of nh-acidic compounds | |
WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
MX2009007742A (es) | Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada. | |
HK1096034A1 (en) | A solid dosage form comprising a fibrate | |
MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
WO2008027350A3 (en) | Acetaminophen pharmaceutical compositions | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
NZ595127A (en) | Stable pharmaceutical composition for atherosclerosis | |
WO2007106550A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
WO2007122635A3 (en) | Controlled release formulation comprising anti-epileptic drugs | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
IL187678A (en) | Causes and prevents liver disease containing a derivative of pyrazolopyrimidinone | |
UA96622C2 (ru) | Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования | |
IL187632A (en) | 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive | |
MXPA06000332A (es) | Nueva composicion farmaceutica solida que comprende amisulprida. | |
PL377683A1 (pl) | System terapeutyczny zawierający amoksycylinę i kwas klawulanowy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |